Pacira Pharmaceuticals (PCRX) PT Raised to $94 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.40 +0.03%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $94.00 (from $79.00) while maintaining a Overweight rating.
You May Also Be Interested In
- BNP Paribas Exane Downgrades Randstad NV (RAND:NA) (RANJF) to Underperform
- BNP Paribas Exane Downgrades Manpower Inc. (MAN) to Neutral
- V-Guard Industries Ltd (VGRD:IN) PT Lowered to INR414 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
